For investors evaluating emerging medical technology companies, the competitive advantages behind a product can be as important as financial results. That was the focus of a recent Medsider interview with Dr. Sudhir Srivastava, founder, chairman and CEO of SS Innovations International (NASDAQ: SSII), who discussed the company’s strategy to broaden access to robotic surgery through lower-cost technology, physician training and remote surgical capabilities.
Rather than concentrating solely on competing with existing robotic surgery platforms, Dr. Srivastava described SS Innovations’ objective as expanding access to hospitals and patients that have historically been unable to adopt robotic surgery because of equipment costs and operating expenses. The company’s SSi Mantra system was designed to reduce the cost of robotic surgery while supporting multiple specialties, including cardiac surgery. Affordability and accessibility remain the company’s core priorities as it expands its surgical robotics platform globally.
Artificial intelligence, automation, and new robotic platforms remain central to the company’s long-term product roadmap. Telesurgery and teleproctoring are becoming important differentiators, allowing expert surgeons to support complex procedures remotely. The company has already demonstrated success in this area, having completed more than 170 telesurgeries as part of its operational history.
SS Innovations has installed more than 200 robotic systems and completed more than 11,700 robotic procedures. The company is pursuing FDA and European regulatory approvals while expanding into additional international markets. This regulatory push, combined with an established track record of clinical use, positions the company to potentially compete with larger players in the surgical robotics space.
The company’s strategy emphasizes that cost reduction does not have to come at the expense of capability. By designing the SSi Mantra system to be more affordable, SS Innovations aims to penetrate markets where robotic surgery adoption has been limited due to financial constraints. This approach could open new revenue streams and provide a competitive edge in both developed and emerging markets.
Investors interested in the medical technology sector may find SS Innovations’ focus on accessibility and remote surgery capabilities noteworthy. The company’s progress in regulatory approvals and international expansion will be key factors to watch. For the latest news and updates relating to SSII, visit the company’s newsroom at https://ibn.fm/SSII.
